<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               8  USE IN SPECIFIC POPULATIONS<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                        <BR>                           <BR>                              Pregnancy/Lactation – Pregnant or nursing<BR>women should not use unless potential benefit justifies potential risk to<BR>fetus or infant. (8.1,<BR>                                  8.3)<BR>                              <BR>                           <BR>                           <BR>                              Hepatic Insufficiency – Increased exposure<BR>(AUC) to atomoxetine than<BR>with normal subjects in EM subjects with moderate (Child–Pugh Class<BR>B) (2–fold increase) and severe (Child–Pugh Class C) (4–fold<BR>increase). (8.6)<BR>                              <BR>                           <BR>                           <BR>                              Renal Insufficiency – Higher systemic exposure to atomoxetine than<BR>healthy subjects for EM subjects with end stage renal disease - no difference<BR>when exposure corrected for mg/kg dose. (8.7)<BR>                              <BR>                           <BR>                           <BR>                              Patients with Concomitant Illness – Does<BR>not worsen tics in patients with ADHD and comorbid Tourette’s Disorder. (8.10)<BR>                              <BR>                           <BR>                           <BR>                              <BR>Patients with Concomitant Illness - Does not worsen anxiety in patients with ADHD and comorbid Anxiety Disorders. (8.10)<BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.1  Pregnancy<BR>                     <BR>                        <BR>                           Pregnancy<BR>Category C — Pregnant rabbits were treated with up to 100 mg/kg/day<BR>of atomoxetine by gavage throughout the period of organogenesis. At this dose,<BR>in 1 of 3 studies, a decrease in live fetuses and an increase in early resorptions<BR>was observed. Slight increases in the incidences of atypical origin of carotid<BR>artery and absent subclavian artery were observed. These findings were observed<BR>at doses that caused slight maternal toxicity. The no-effect dose for these<BR>findings was 30 mg/kg/day. The 100 mg/kg dose is approximately<BR>23 times the maximum human dose on a mg/m2 basis;<BR>plasma levels (AUC) of atomoxetine at this dose in rabbits are estimated to<BR>be 3.3 times (extensive metabolizers) or 0.4 times (poor metabolizers) those<BR>in humans receiving the maximum human dose.<BR>                        Rats were treated with up to approximately 50 mg/kg/day<BR>of atomoxetine (approximately 6 times the maximum human dose on a mg/m2 basis)<BR>in the diet from 2 weeks (females) or 10 weeks (males) prior to mating through<BR>the periods of organogenesis and lactation. In 1 of 2 studies, decreases in<BR>pup weight and pup survival were observed. The decreased pup survival was<BR>also seen at 25 mg/kg (but not at 13 mg/kg).<BR>In a study in which rats were treated with atomoxetine in the diet from 2<BR>weeks (females) or 10 weeks (males) prior to mating throughout the period<BR>of organogenesis, a decrease in fetal weight (female only) and an increase<BR>in the incidence of incomplete ossification of the vertebral arch in fetuses<BR>were observed at 40 mg/kg/day (approximately 5 times the<BR>maximum human dose on a mg/m2 basis) but not at<BR>20 mg/kg/day.<BR>                        No adverse fetal effects were seen when pregnant rats were treated with<BR>up to 150 mg/kg/day (approximately 17 times the maximum human<BR>dose on a mg/m2 basis) by gavage throughout the<BR>period of organogenesis.<BR>                        No adequate and well-controlled studies have been conducted in pregnant<BR>women. STRATTERA should not be used during pregnancy unless the potential<BR>benefit justifies the potential risk to the fetus.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.2  Labor and Delivery<BR>                     <BR>                        Parturition in rats was not affected by atomoxetine.<BR>The effect of STRATTERA on<BR>labor and delivery in humans is unknown.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.3  Nursing Mothers<BR>                     <BR>                        Atomoxetine and/or its metabolites were excreted<BR>in the milk of rats. It is not known if atomoxetine is<BR>excreted in human milk. Caution should be exercised if STRATTERA is<BR>administered to a nursing woman.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.4  Pediatric Use<BR>                     <BR>                        Anyone considering the use of STRATTERA in<BR>a child or adolescent must balance the potential risks with the clinical need <BR>                              [see<BR>Boxed Warning<BR>                           <BR>                           <BR>                               and Warnings and Precautions<BR>(5.1)]<BR>                           .<BR>                        The pharmacokinetics of atomoxetine in<BR>children and adolescents are similar to those in adults. The safety, efficacy,<BR>and pharmacokinetics of STRATTERA in<BR>pediatric patients less than 6 years of age have not been evaluated.<BR>                        A study was conducted in young rats to evaluate the effects of atomoxetine<BR>on growth and neurobehavioral and sexual development. Rats were treated with<BR>1, 10, or 50 mg/kg/day (approximately 0.2, 2, and 8 times,<BR>respectively, the maximum human dose on a mg/m2 basis)<BR>of atomoxetine given by gavage from the early postnatal period (Day 10 of<BR>age) through adulthood. Slight delays in onset of vaginal patency (all doses)<BR>and preputial separation (10 and 50 mg/kg), slight decreases<BR>in epididymal weight and sperm number (10 and 50 mg/kg),<BR>and a slight decrease in corpora lutea (50 mg/kg) were seen,<BR>but there were no effects on fertility or reproductive performance. A slight<BR>delay in onset of incisor eruption was seen at 50 mg/kg.<BR>A slight increase in motor activity was seen on Day 15 (males at 10 and 50 mg/kg<BR>and females at 50 mg/kg) and on Day 30 (females at 50 mg/kg)<BR>but not on Day 60 of age. There were no effects on learning and memory tests.<BR>The significance of these findings to humans is unknown.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.5  Geriatric Use<BR>                     <BR>                        The safety, efficacy and pharmacokinetics of STRATTERA in<BR>geriatric patients have not been evaluated.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.6  Hepatic Insufficiency<BR>                     <BR>                        Atomoxetine exposure (AUC) is increased, compared with normal subjects,<BR>in EM subjects with moderate (Child–Pugh Class B) (2–fold<BR>increase) and severe (Child–Pugh Class C) (4–fold<BR>increase) hepatic insufficiency. Dosage adjustment is recommended for patients<BR>with moderate or severe hepatic insufficiency <BR>                              [see Dosage<BR>and Administration (2.3)]<BR>                           .<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.7  Renal Insufficiency<BR>                     <BR>                        EM subjects with end stage renal disease had<BR>higher systemic exposure to atomoxetine than healthy subjects (about a 65% increase), but there<BR>was no difference when exposure was corrected for mg/kg dose. STRATTERA can<BR>therefore be administered to ADHD patients with end stage renal disease or<BR>lesser degrees of renal insufficiency using the normal dosing regimen.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.8  Gender<BR>                     <BR>                        Gender did not influence atomoxetine disposition.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.9  Ethnic Origin<BR>                     <BR>                        Ethnic origin did not influence atomoxetine disposition<BR>(except that PMs are more common in Caucasians).<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     8.10  Patients with Concomitant Illness<BR>                     <BR>                        <BR>                           Tics in<BR>patients with ADHD and comorbid Tourette’s Disorder —<BR>Atomoxetine administered in a flexible dose range of 0.5 to 1.5 mg/kg/day<BR>(mean dose of 1.3 mg/kg/day) and placebo were compared in 148 randomized pediatric<BR>(age 7-17 years) subjects with a DSM-IV diagnosis of ADHD and comorbid tic<BR>disorder in an 18 week, double- blind, placebo-controlled study in which the<BR>majority (80%) enrolled in this trial with Tourette’s Disorder (Tourette’s<BR>Disorder: 116 subjects; chronic motor tic disorder: 29 subjects). A non-inferiority<BR>analysis revealed that STRATTERA did not worsen tics in these patients as<BR>determined by the Yale Global Tic Severity Scale Total Score (YGTSS). Out<BR>of 148 patients who entered the acute treatment phase, 103 (69.6%) patients<BR>discontinued the study. The primary reason for discontinuation in both the<BR>atomoxetine (38 of 76 patients, 50.0%) and placebo (45 of 72 patients, 62.5%)<BR>treatment groups was identified as lack of efficacy with most of the patients<BR>discontinuing at Week 12. This was the first visit where patients with a CGI-S≥4<BR>could also meet the criteria for “clinical non-responder” (CGI-S<BR>remained the same or increased from study baseline) and be eligible to enter<BR>an open-label extension study with atomoxetine.<BR>                        <BR>                           Anxiety in patients with ADHD and comorbid Anxiety Disorders - In two post-marketing, double-blind, placebo-controlled trials, it has been demonstrated that treating patients with ADHD and comorbid anxiety disorders with STRATTERA does not worsen their anxiety.<BR>                        <BR>In a 12-week double-blind, placebo-controlled trial, 176 patients, aged 8-17, who met DSM-IV criteria for ADHD and at least one of the anxiety disorders of separation anxiety disorder, generalized anxiety disorder or social phobia were randomized. Following a 2-week double-blind placebo lead-in, STRATTERA was initiated at 0.8 mg/kg/day with increase to a target dose of 1.2 mg/kg/day (median dose 1.30 mg/kg/day +/- 0.29 mg/kg/day). STRATTERA did not worsen anxiety in these patients as determined by the Pediatric Anxiety Rating Scale (PARS). Of the 158 patients who completed the double-blind placebo lead-in, 26 (16%) patients discontinued the study.<BR>                        <BR>In a separate 16-week, double-blind, placebo-controlled trial, 442 patients aged 18-65, who met DSM-IV criteria for adult ADHD and social anxiety disorder (23% of whom also had Generalized Anxiety Disorder) were randomized. Following a 2-week double-blind placebo lead-in, STRATTERA was initiated at 40 mg/day to a maximum dose of 100 mg/day (mean daily dose 83 mg/day +/- 19.5 mg/day). STRATTERA did not worsen anxiety in these patients as determined by the Liebowitz Social Anxiety Scale (LSAS). Of the 436 patients who completed the double-blind placebo lead-in, 172 (39.4%) patients discontinued the study.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>